Drugs / AGURACINGENE CADOPARVOVEC
AGURACINGENE CADOPARVOVEC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03758404 | Aug 2019 → Jun 2021 | achromatopsia | MeiraGTx UK II Ltd | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGURACINGENE CADOPARVOVEC | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802268 ↗ |
| Known as | AAV- CNGA3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03758404 ↗ |
| Known as | Aguracingen cadoparvovec | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802268 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-associated virus (AAV) gene therapy” NCT03758404 ↗ |
| Route | Other | “Subretinal administration” NCT03758404 ↗ |